Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 4.63
NAS:RGLS's Cash to Debt is ranked lower than
63% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NAS:RGLS: 4.63 )
Ranked among companies with meaningful Cash to Debt only.
NAS:RGLS' s Cash to Debt Range Over the Past 10 Years
Min: 1.76  Med: 8.86 Max: No Debt
Current: 4.63
Equity to Asset 0.63
NAS:RGLS's Equity to Asset is ranked lower than
56% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:RGLS: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
NAS:RGLS' s Equity to Asset Range Over the Past 10 Years
Min: -1.26  Med: 0.72 Max: 0.89
Current: 0.63
-1.26
0.89
F-Score: 2
Z-Score: -2.14
M-Score: -3.67
WACC vs ROIC
19.16%
-3731.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -574.27
NAS:RGLS's Operating margin (%) is ranked lower than
71% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. NAS:RGLS: -574.27 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:RGLS' s Operating margin (%) Range Over the Past 10 Years
Min: -585.6  Med: -139.6 Max: -51.76
Current: -574.27
-585.6
-51.76
Net-margin (%) -573.63
NAS:RGLS's Net-margin (%) is ranked lower than
72% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:RGLS: -573.63 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:RGLS' s Net-margin (%) Range Over the Past 10 Years
Min: -739.08  Med: -158.99 Max: -55.13
Current: -573.63
-739.08
-55.13
ROE (%) -66.60
NAS:RGLS's ROE (%) is ranked lower than
70% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NAS:RGLS: -66.60 )
Ranked among companies with meaningful ROE (%) only.
NAS:RGLS' s ROE (%) Range Over the Past 10 Years
Min: -169.02  Med: -46.91 Max: -24
Current: -66.6
-169.02
-24
ROA (%) -52.39
NAS:RGLS's ROA (%) is ranked lower than
68% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NAS:RGLS: -52.39 )
Ranked among companies with meaningful ROA (%) only.
NAS:RGLS' s ROA (%) Range Over the Past 10 Years
Min: -52.39  Med: -35.46 Max: -16.48
Current: -52.39
-52.39
-16.48
ROC (Joel Greenblatt) (%) -660.05
NAS:RGLS's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NAS:RGLS: -660.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:RGLS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1544.17  Med: -534.92 Max: -450.68
Current: -660.05
-1544.17
-450.68
Revenue Growth (3Y)(%) -36.10
NAS:RGLS's Revenue Growth (3Y)(%) is ranked lower than
82% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NAS:RGLS: -36.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:RGLS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -89.6 Max: -36.1
Current: -36.1
EBITDA Growth (3Y)(%) -18.80
NAS:RGLS's EBITDA Growth (3Y)(%) is ranked lower than
71% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NAS:RGLS: -18.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:RGLS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -73.7 Max: -18.8
Current: -18.8
EPS Growth (3Y)(%) -20.10
NAS:RGLS's EPS Growth (3Y)(%) is ranked lower than
68% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NAS:RGLS: -20.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:RGLS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -75.3 Max: -20.1
Current: -20.1
» NAS:RGLS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

RGLS Guru Trades in

Q2 2015

RGLS Guru Trades in Q2 2015

Jim Simons 57,000 sh (New)
» More
Q3 2015

RGLS Guru Trades in Q3 2015

Jim Simons Sold Out
» More
Q3 2016

RGLS Guru Trades in Q3 2016

Jim Simons 645,000 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with RGLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ENZY, NAS:ABUS, NAS:AKAO, NAS:AXSM, NAS:XENE, NAS:VVUS, NAS:NYMX, NAS:AVXL, NAS:RDHL, NAS:CASC, OTCPK:SPRWF, AMEX:NAVB, OTCPK:OGRMF, OTCPK:PAIOF, NAS:ATHX, NAS:OVAS, NAS:GTXI, NAS:GLYC, NAS:FBIO, NAS:CXRX » details
Traded in other countries:7RG.Germany,
Regulus Therapeutics Inc is a biopharmaceutical company. The Company is engaged in discovering and developing drugs that target micro RNAs to treat various diseases.

Regulus Therapeutics Inc was originally formed as a Delaware limited liability company under the name Regulus Therapeutics LLC on September 6, 2007. In January 2009, it converted Regulus Therapeutics LLC to a Delaware corporation and changed its name to Regulus Therapeutics Inc. The Company is a biopharmaceutical company engaged in discovering and developing first-in-class drugs that target microRNAs to treat various diseases. microRNAs are naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. The Company has established Regulus microMarkers, a division engaged in identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners. Through its microRNA target identification and validation efforts it has developed proprietary technologies for microRNA profiling and analysis of human clinical samples such as tissue. The Company has licensed patent rights from Julius-Maximilians-Universität Würzburg and Bayerische Patent Allianz GmBH, which rights encompass the use of anti-miR therapeutics targeting miR-21 for the treatment of fibrosis, including kidney, liver, lung and cardiac fibrosis. It has also license from Stanford University, or Stanford, to patent rights concerning the use of anti-miR therapeutics targeting miR-122 for the treatment of HCV infection. It has also licensed from ETH Zürich to patent rights related to the use of anti-miR therapeutics targeting miR-103/107 for the treatment of metabolic disorders, including type 2 diabetes. The Company's portfolio of exclusively and jointly owned patent and patent applications is currently composed of over 150 U.S. and foreign patents and patent applications with claims to compositions-of-matter or methods related to its microRNA drug products and microRNA product platform. The Company faces competition from other biotechnology and pharmaceutical companies. Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those the Company is developing.

Ratios

vs
industry
vs
history
P/B 2.15
RGLS's P/B is ranked higher than
74% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. RGLS: 2.15 )
Ranked among companies with meaningful P/B only.
RGLS' s P/B Range Over the Past 10 Years
Min: 1.71  Med: 3.64 Max: 12.95
Current: 2.15
1.71
12.95
P/S 12.73
RGLS's P/S is ranked higher than
50% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. RGLS: 12.73 )
Ranked among companies with meaningful P/S only.
RGLS' s P/S Range Over the Past 10 Years
Min: 0.1  Med: 17.73 Max: 111.09
Current: 12.73
0.1
111.09
Current Ratio 7.82
RGLS's Current Ratio is ranked higher than
70% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. RGLS: 7.82 )
Ranked among companies with meaningful Current Ratio only.
RGLS' s Current Ratio Range Over the Past 10 Years
Min: 1.64  Med: 9.24 Max: 12.36
Current: 7.82
1.64
12.36
Quick Ratio 7.82
RGLS's Quick Ratio is ranked higher than
71% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. RGLS: 7.82 )
Ranked among companies with meaningful Quick Ratio only.
RGLS' s Quick Ratio Range Over the Past 10 Years
Min: 1.64  Med: 9.24 Max: 12.36
Current: 7.82
1.64
12.36
Days Sales Outstanding 8.67
RGLS's Days Sales Outstanding is ranked higher than
88% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. RGLS: 8.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
RGLS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.47  Med: 13.04 Max: 176.2
Current: 8.67
1.47
176.2

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.70
RGLS's 3-Year Average Share Buyback Ratio is ranked lower than
57% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. RGLS: -13.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RGLS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -719.3  Med: -13.7 Max: 0
Current: -13.7
-719.3
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.13
RGLS's Price/Net Cash is ranked higher than
79% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. RGLS: 3.13 )
Ranked among companies with meaningful Price/Net Cash only.
RGLS' s Price/Net Cash Range Over the Past 10 Years
Min: 2.31  Med: 4.63 Max: 8.92
Current: 3.13
2.31
8.92
Price/Net Current Asset Value 2.54
RGLS's Price/Net Current Asset Value is ranked higher than
82% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. RGLS: 2.54 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RGLS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.04  Med: 4.39 Max: 8.11
Current: 2.54
2.04
8.11
Price/Tangible Book 2.11
RGLS's Price/Tangible Book is ranked higher than
80% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. RGLS: 2.11 )
Ranked among companies with meaningful Price/Tangible Book only.
RGLS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.74  Med: 4.15 Max: 7.36
Current: 2.11
1.74
7.36
Price/Median PS Value 0.69
RGLS's Price/Median PS Value is ranked higher than
73% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. RGLS: 0.69 )
Ranked among companies with meaningful Price/Median PS Value only.
RGLS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 1.15 Max: 5.19
Current: 0.69
0.01
5.19
Earnings Yield (Greenblatt) (%) -75.48
RGLS's Earnings Yield (Greenblatt) (%) is ranked lower than
93% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. RGLS: -75.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RGLS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -106.4  Med: 39.35 Max: 44.4
Current: -75.48
-106.4
44.4

More Statistics

Revenue (TTM) (Mil) $12.04
EPS (TTM) $ -1.30
Beta2.46
Short Percentage of Float6.91%
52-Week Range $2.13 - 10.25
Shares Outstanding (Mil)52.92

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1 1 1 3
EPS ($) -1.51 -1.39 -1.53 -1.75
EPS w/o NRI ($) -1.51 -1.39 -1.53 -1.75
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for RGLS

Headlines

Articles On GuruFocus.com
Top Insider Buys, Sells of the Week Feb 26 2016 
Weekly CEO Sells Highlight: Hovnanian Enterprises Inc, Regulus Therapeutics Inc, Monster Beverage Co Apr 27 2015 
Regulus Therapeutics (RGLS) microRNA Therapeutic Milestone Payment, Dave & Buster's Entertainment (P Apr 08 2015 
This Week’s Pharma Highlights Mar 19 2015 
Weekly CEO Sells Highlight: Kimberly-Clark Corp, Regulus Therapeutics Inc, Prologis Inc, and Adobe S Feb 01 2015 

More From Other Websites
Regulus to Announce New Drug Development Candidates at R&D Day on December 6, 2016 Nov 22 2016
Regulus to Announce New Drug Development Candidates at R&D Day on December 6, 2016 Nov 22 2016
REGULUS THERAPEUTICS INC. Financials Nov 08 2016
ETF’s with exposure to Regulus Therapeutics, Inc. : November 4, 2016 Nov 04 2016
Regulus Therapeutics, Inc. :RGLS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016 Nov 03 2016
Edited Transcript of RGLS earnings conference call or presentation 1-Nov-16 9:00pm GMT Nov 02 2016
REGULUS THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report Nov 02 2016
Regulus reports 3Q loss Nov 01 2016
Regulus reports 3Q loss Nov 01 2016
REGULUS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 01 2016
Regulus Reports Third Quarter 2016 Financial Results Nov 01 2016
Regulus Reports Third Quarter 2016 Financial Results Nov 01 2016
Q3 2016 Regulus Therapeutics Inc Earnings Release - After Market Close Nov 01 2016
Regulus to Release Third Quarter Financial Results on November 1, 2016 Oct 25 2016
Regulus to Release Third Quarter Financial Results on November 1, 2016 Oct 25 2016
Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Oct 06 2016
Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Oct 06 2016
3 Battered Biotechs That Could Turn Things Around Oct 05 2016
Regulus Appoints Timothy M. Wright, M.D. as Chief Research and Development Officer Oct 05 2016
ETF’s with exposure to Regulus Therapeutics, Inc. : October 4, 2016 Oct 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)